The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Open accessAbstract
Convalescent plasma is currently one of the leading treatments for COVID-19, but there is a paucity of data identifying therapeutic efficacy. A comprehensive analysis of the antibody responses in potential plasma donors and an understanding of the clinical and demographic factors that drive variant antibody responses is needed. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated by a SARS-CoV-2 virus neutralization assay using Vero-E6-TMPRSS2 cells, commercial IgG and IgA ELISA to Spike (S) protein S1 domain (Euroimmun), IgA, IgG and IgM indirect ELISAs to the full-length S or S-receptor binding domain (S-RBD), and an IgG avidity assay. Multiple linear regression and predictive models were utilized to assess the correlations between antibody responses with demographic and clinical characteristics. IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population. Of the 126 plasma samples, 101 (80%) had detectable neutralizing titers. Using neutralization titer as the reference, the sensitivity of the IgG ELISAs ranged between 95-98%, but specificity was only 20-32%. Male sex, older age, and hospitalization with COVID-19 were all consistently associated with increased antibody responses across the serological assays. Neutralizing antibody titers were reduced over time in contrast to overall antibody responses. There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Using the Margins Command to Estimate and Interpret Adjusted Predictions and Marginal Effects
Williams, R. (2012) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x1201200209 · Cited by 2,141
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,411
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd2223 · Cited by 1,037
Considering how biological sex impacts immune responses and COVID-19 outcomes
Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C., & Klein, S. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0348-8 · Cited by 932
Self-citationThe convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Self-citationDeployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Self-citationStructural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 649
Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00157 · Cited by 528
Sex and Gender Differences in the Outcomes of Vaccination over the Life Course
Flanagan, K. L., Fink, A. L., Plebanski, M., & Klein, S. L. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060718 · Cited by 508
Self-citationConvalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily-Marcus, A., Bander, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 493
Self-citationEarly safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 471
Self-citationWang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa721 · Cited by 359
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 347
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives
Klasse, P. J. (2014) · Advances in Biology · doi:10.1155/2014/157895 · Cited by 226
Schaecher, S. R., Mackenzie, J. M., & Pekosz, A. (2007) · Journal of Virology · doi:10.1128/jvi.01691-06 · Cited by 176
Self-citationWang, Q., Du, Q., Guo, B., Mu, D., Lu, X., Ma, Q., Guo, Y., Li, F., Zhang, B., Zhang, G., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00375-20 · Cited by 138
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Hegerova, L. T., Gooley, T. A., Sweerus, K. A., Maree, C. L., Bailey, N., Bailey, M., Dunleavy, V., Patel, K., Alcorn, K. W., Haley, R., et al. (2020) · Blood · doi:10.1182/blood.2020006964 · Cited by 133
VanBlargan, L. A., Goo, L., & Pierson, T. C. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00024-15 · Cited by 118
Severe Acute Respiratory Syndrome Coronavirus Gene 7 Products Contribute to Virus-Induced Apoptosis
Schaecher, S. R., Touchette, E., Schriewer, J. M., Buller, R. M. L., & Pekosz, A. S. (2007) · Journal of Virology · doi:10.1128/jvi.01266-07 · Cited by 85
Self-citationAn immunosuppressed Syrian golden hamster model for SARS-CoV infection
Schaecher, S. R., Stabenow, J. M., Oberle, C., Schriewer, J. M., Buller, R. M. L., Sagartz, J. E., & Pekosz, A. S. (2008) · Virology · doi:10.1016/j.virol.2008.07.026 · Cited by 79
Self-citationVanderven, H. A., & Kent, S. J. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12312 · Cited by 61
Cited by
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik-Wang, J. M. (2021) · JAMA · doi:10.1001/jama.2021.7489 · Cited by 955
Self-citationAging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
Self-citationBoyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik-Wang, J. M. (2021) · JAMA · doi:10.1001/jama.2021.4385 · Cited by 508
Self-citationConvalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily-Marcus, A., Bander, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 493
Self-citation
Metadata
- Authors
- Klein, S. L., Pekosz, A., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., Shrestha, R., Wu, A. A., Hughes, R. M., Burgess, I., Caturegli, P., Laeyendecker, O., Quinn, T. C., Sullivan, D., Shoham, S., Redd, A. D., Bloch, E. M., Casadevall, A., & Tobian, A. A. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-10-19
- Volume
- 130
- Issue
- 11
- Pages
- 6141-6150
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3048117004
- Cited by
- 432
- References
- 33
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.